Dr. Marcelo Cypel, MD MSc
Claim this profileUniversity Health Network (Toronto General Hospital)
Studies Cancer
Studies Lung Cancer
4 reported clinical trials
7 drugs studied
Affiliated Hospitals
Clinical Trials Marcelo Cypel, MD MSc is currently running
Cold Lung Preservation
for Lung Transplant
Despite lung transplantation (LTx) being the most effective treatment for end-stage lung disease, its success rate is lower than that of other solid organ transplantations. Primary graft dysfunction (PGD) is the most common post-operative complication and a major factor in early mortality and morbidity, affecting \~25% of lung transplant patients. Induced by ischemia reperfusion, PGD represents a severe and acute lung injury that occurs within the first 72 hours after transplantation, and has a significant impact on short- and long-term outcomes, and a significant increase in treatment costs. Any intervention that reduces the risk of PGD will lead to major improvements in short- and long-term transplant outcomes and health care systems. One of the main strategies to reduce the risk and severity of post-transplant PGD is to improve pre-transplant donor lung preservation methods. In current practice, lung preservation is typically performed by cold flushing the organ with a specialized preservation solution, followed by subsequent hypothermic storage on ice (\~4°C). This method continues to be used and applied across different organ systems due to its simplicity and low cost. Using this method for the preservation of donor lungs, the current maximum accepted preservation times have been limited to approximately 6-8h. While the goal of hypothermic storage is to sustain cellular viability during ischemic time through reduced cellular metabolism, lower organ temperature has also been shown to progressively favor mitochondrial dysfunction. Therefore, the ideal temperature for donor organ preservation remains to be defined and should maintain a balance between avoidance of mitochondrial dysfunction and prevention of cellular exhaustion. In addition to that, safe and longer preservation times can lead to multiple advantages such as moving overnight transplants to daytime, more flexibility to transplant logistics, more time for proper donor to recipient matching etc. Building on pre-clinical research suggesting that 10°C may be the optimal lung storage temperature, a prospective, multi-center, non-randomized clinical trial was conducted at University Health Network, Medical University of Vienna and Puerta de Hierro Majadahonda University Hospital. Donor lungs meeting criteria for direct transplantation and with cross clamp times between 6:00pm - 4:00am were intentionally delayed to an earliest allowed start time of 6:00am and a maximum preservation time from donor cold flush to recipient anesthesia start time of 12 hours. Lungs were retrieved and transported in the usual fashion using a cooler with ice and transferred to a 10°C temperature-controlled cooler upon arrival to transplant hospital until implantation. The primary outcome of this study was incidence of Primary Graft Dysfunction (PGD) Grade 3 at 72h, with secondary endpoints including: recipient time on the ventilator, ICU Length of Stay (LOS), hospital LOS, 30-day survival and lung function at 1-year. Outcomes were compared to a contemporaneous conventionally transplanted recipient cohort using propensity score matching at a 1:2 ratio. 70 patients were included in the study arm. Post-transplant outcomes were comparable between the two groups for up to 1 year. Thus, intentional prolongation of donor lung preservation at 10°C was shown to be clinically safe and feasible. In the current study design, the investigators will conduct a multi-centre, non-inferiority, randomized, controlled trial of 300 participants to compare donor lung preservation from the time of explant to implant at \~10°C in X°Port Lung Transport Device (Traferox Technologies Inc.) vs a standard ice cooler. When eligible donor lungs become available for a consented recipient, the lungs will be randomized to undergo a preservation protocol using either 10°C (X°Port Lung Transport Device, Traferox Technologies Inc.) or standard of care. The primary outcome of the study is incidence of ISHLT Primary Graft Dysfunction Grade 3 at 72 hours. Post-transplant outcomes will be followed for one year.
Recruiting1 award N/A
IVLP with Oxaliplatin
for Colorectal Cancer Spread to Lungs
This trial is testing a new method of delivering chemotherapy directly into the lungs during surgery to treat patients with colorectal cancer that has spread to the lungs. The goal is to kill cancer cells in the lung while minimizing side effects to other organs. The study will determine the safest dose of the chemotherapy drug oxaliplatin when delivered using this method.
Recruiting1 award Phase 1
More about Marcelo Cypel, MD MSc
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Marcelo Cypel, MD MSc has experience with
- Lung Transplantation After 10°C Donor Lung Preservation
- Lung Transplantation After Standard Ice Cooler Donor Lung Preservation
- Doxorubicin
- In Vivo Lung Perfusion
- Oxaliplatin
- Chemotherapy
Breakdown of trials Marcelo Cypel, MD MSc has run
Colorectal Cancer
Lung Transplant
Organ Preservation
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Marcelo Cypel, MD MSc specialize in?
Marcelo Cypel, MD MSc focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Marcelo Cypel, MD MSc currently recruiting for clinical trials?
Yes, Marcelo Cypel, MD MSc is currently recruiting for 3 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Marcelo Cypel, MD MSc has studied deeply?
Yes, Marcelo Cypel, MD MSc has studied treatments such as Lung transplantation after 10°C donor lung preservation, Lung transplantation after standard ice cooler donor lung preservation, Doxorubicin.
What is the best way to schedule an appointment with Marcelo Cypel, MD MSc?
Apply for one of the trials that Marcelo Cypel, MD MSc is conducting.
What is the office address of Marcelo Cypel, MD MSc?
The office of Marcelo Cypel, MD MSc is located at: University Health Network (Toronto General Hospital), Toronto, Ontario M5G 2C4 Canada. This is the address for their practice at the University Health Network (Toronto General Hospital).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.